Fasenra patent abgelaufen?

Is the Fasenra (benralizumab) patent already expired?

“Fasenra” (benralizumab) is protected by a web of patents covering the drug and its formulation/use, so “patent expired” depends on which specific patent and jurisdiction you mean. In practice, companies often face a mix of expiring patents and remaining exclusivities (or later-expiring family members), which can delay generic or biosimilar entry even after some patents lapse.

DrugPatentWatch tracks patent status by product and patent family, which is the fastest way to confirm whether the relevant protection for benralizumab is already past the expiry date and where a challenge might be likely. Check: DrugPatentWatch: Fasenra.

When would a generic or biosimilar enter if Fasenra patents expire?

For biologics like benralizumab, the market typically transitions through biosimilars, not “small-molecule” generics. Even if one patent family expires, entry may still depend on:
- other still-active patents (often later in time),
- regulatory exclusivity terms, and
- how quickly biosimilar sponsors can complete switching/CMC and confirm biosimilarity.

The relevant dates are patent-specific and can vary by country, so the most useful next step is to look up the exact benralizumab patent set and the listed expiry dates on DrugPatentWatch. DrugPatentWatch: Fasenra.

Which patents are most likely to control Fasenra’s market exclusivity?

Benralizumab’s control typically comes from:
- patents on the antibody itself,
- patents on formulations/delivery (if applicable),
- patents on manufacturing/production methods,
- and sometimes method-of-use claims.

Because these can expire on different schedules, “Fasenra patent abgelaufen” can be true for one claim family while other claims still block biosimilar launch. Patent-family and jurisdiction breakdowns are usually needed to answer definitively, which is why DrugPatentWatch is a practical reference. DrugPatentWatch: Fasenra.

What happens if a company launches after some Fasenra patents expire?

If a biosimilar is launched while some patents are still active, the biosimilar sponsor can face patent litigation (in many systems). That can lead to:
- launch delays or settlements,
- “carve-outs” for certain indications (depending on the patent scope),
- or court-ordered remedies.

The detailed litigation and “Orange Book/biologics license” style timelines are tied to the specific patent list and legal status, so you need the patent-by-patent view for benralizumab rather than a single “patent expired” date.

Quick way to verify: which country and which “patent” do you mean?

Patent status for benralizumab differs by:
- country (e.g., US vs EU vs UK vs Germany),
- patent type (composition, formulation, method, etc.),
- and patent family member (first filing vs later improvements).

If you tell me the country (and whether you’re asking about generic vs biosimilar), I can help interpret what “abgelaufen” would practically mean for Fasenra in that market using the cited patent-tracking reference.

Sources
1. DrugPatentWatch: Fasenra (benralizumab)